Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Abstract In Alzheimer’s disease (AD), tau phosphorylation in the brain and its subsequent release into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease evolution. The main aim of our study was to characterize the pattern of changes in phosphorylated tau (p‐tau) in...

Full description

Bibliographic Details
Main Authors: Marc Suárez‐Calvet, Thomas K Karikari, Nicholas J Ashton, Juan Lantero Rodríguez, Marta Milà‐Alomà, Juan Domingo Gispert, Gemma Salvadó, Carolina Minguillon, Karine Fauria, Mahnaz Shekari, Oriol Grau‐Rivera, Eider M Arenaza‐Urquijo, Aleix Sala‐Vila, Gonzalo Sánchez‐Benavides, José Maria González‐de‐Echávarri, Gwendlyn Kollmorgen, Erik Stoops, Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, José Luis Molinuevo, for the ALFA Study
Format: Article
Language:English
Published: Wiley 2020-12-01
Series:EMBO Molecular Medicine
Subjects:
Alzheimer’s disease
biomarker
cerebrospinal fluid
plasma
tau
Online Access:https://doi.org/10.15252/emmm.202012921

Internet

https://doi.org/10.15252/emmm.202012921

Similar Items